Vitae Pharmaceuticals: Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials Of BACE Inhibitor BI1181181/VTP-37948 In Alzheimer's Disease

Loading...
Loading...
Co announced positive top-line results from clinical trials in treatment and prevention of Alzheimer's disease as part of the collaboration with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. The two Phase 1 clinical trials of BI1181181/VTP-37948, an orally active beta secretase inhibitor discovered by Vitae and developed by Boehringer Ingelheim, are randomized, placebo-controlled single dose studies (a single rising dose and a proof of mechanism study) that involved a total of 68 healthy volunteers. The single rising dose trial assessed the safety, tolerability and pharmacokinetic profile of BI1181181/VTP-37948. In the study, BI1181181/VTP-37948 was safe and generally well-tolerated across all dose levels tested. Also, the results indicated a half-life of between 16 and 19 hours, supporting a once-daily dosing profile.
Posted In: NewsFDAPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...